The Mayo Clinic Breast Cancer SPORE will maximize the number of innovative and high-quality projects in the Developmental Research Program. The goal of this program is to support innovative, scientifically meritorious research projects from which findings can be translated into clinically important applications that will impact diagnosis and management of breast cancer in order to decrease the burden and mortality from this disease. This program will: 1) encourage and solicit innovative translational laboratory, population, and clinical study proposals;2) encourage and support interdisciplinary collaboration in translational research in breast cancer;and 3) generate new hypotheses that can be tested in larger-scale research projects or clinical trials that can impact breast cancer. The availability of this support provides a stimulus for creativity in the research community, a vehicle for encouraging the interaction of basic scientists and translational investigators, and an opportunity for expanding the research spectrum of the SPORE by pursuing new leads based on discoveries and/or opportunities that arise. The Developmental Research Program will provide $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from Mayo Clinic Cancer Center) to each of six projects. There will be the possibility of a second year of support based on demonstration of sufficient progress. A process was established during the initial grant for the Mayo Clinic Breast Cancer SPORE involving a call for applications on an annual basis and a formal peer review utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators. Because of the success of this process, it will be continued. Criteria for selection of projects for funding are based upon scientific merit, originality, qualifications of the applicant, and translational potential. It is expected that support of developmental research projects will result in generation of data that will serve as the basis for additional SPORE-sponsored projects or support through peer reviewed external grant support. It is the intent of the SPORE leadership to encourage and help the investigators to use the data generated by these projects to establish preclinical or clinical trials in breast cancer. In addition the SPORE leadership will work with the investigators to secure independent R01-level funding. Two of the four full Projects in this SPORE renewal have a co-leader who was a Developmental Research Program awardee, which indicates that the Developmental Research Program has been successful in this regard during the previous funding period.
The Developmental Research Program supports innovative and scientifically meritorious research projects that have the greatest potential to be translated into clinically important applications for the prevention, diagnosis and treatment of women with breast cancer.
|Abubakar, Mustapha; Orr, Nick; Daley, Frances et al. (2016) Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res 18:104|
|Cichon, Magdalena A; Moruzzi, Megan E; Shqau, Tiziana A et al. (2016) MYC Is a Crucial Mediator of TGFÎ²-Induced Invasion in Basal Breast Cancer. Cancer Res 76:3520-30|
|de la Hoya, Miguel; Soukarieh, Omar; LÃ³pez-Perolio, Irene et al. (2016) Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet 25:2256-2268|
|Durand, Nisha; Bastea, Ligia I; Long, Jason et al. (2016) Protein Kinase D1 regulates focal adhesion dynamics and cell adhesion through Phosphatidylinositol-4-phosphate 5-kinase type-l Î³. Sci Rep 6:35963|
|Shi, Jiajun; Zhang, Yanfeng; Zheng, Wei et al. (2016) Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer 139:1303-17|
|Lei, Jieping; Rudolph, Anja; Moysich, Kirsten B et al. (2016) Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum Genet 135:137-54|
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|Li, Xu; Wang, Wenqi; Xi, Yuanxin et al. (2016) FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis. Cell Rep 16:487-97|
|Schmidt, Marjanka K; Hogervorst, Frans; van Hien, Richard et al. (2016) Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 34:2750-60|
|Chiba, Akiko; Hoskin, Tanya L; Hallberg, Emily J et al. (2016) Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. Ann Surg Oncol 23:3232-8|
Showing the most recent 10 out of 381 publications